AVNS PEER ANALYSIS

Avanos Medical Inc — metric-by-metric comparison with peers and the industry median

AVNSAvanos Medical Inc

🇺🇸 USA · NYSE · Healthcare · Medical Devices

Value itDuel

Overall Profile & Returns

· Medical Devices

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
AVNSIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
AVNS+101.4%4DX+1,670.8%COH-57.7%SN+4.2%ONCSM+203.3%MEDTR-8.2%
Year-to-Date (YTD)
AVNS+122.0%4DX+8.1%COH-51.5%SN-7.6%ONCSM-4.8%MEDTR+0.3%

Key Metric Comparison

P/E

Lower is better
AVNS4DXCOH23.72SN20.56ONCSM122.41MEDTR596.83Median 27.44

ROE

Higher is better
AVNS-8.6%4DXCOH18.1%SN12.1%ONCSM12.9%MEDTR0.2%Median -8.6%

Net Margin

Higher is better
AVNS-9.7%4DX-3,684.6%COH14.6%SN10.1%ONCSM6.3%MEDTR0.2%Median -5.7%

Revenue Growth

Higher is better
AVNS3.9%4DX-26.0%COH2.0%SNONCSM39.1%MEDTR6.5%Median 7.4%

All Metrics

Valuation
MetricAVNS4DXCOHSNONCSMMEDTRInd. Median
P/E23.7220.56122.41596.8327.44
P/B1.48-74.164.232.4813.361.082.48
EV/EBITDA14.879.8825.4610.9315.23
P/S1.62243.163.472.097.661.182.66
Financial Health
MetricAVNS4DXCOHSNONCSMMEDTRInd. Median
Current Ratio2.486.572.462.572.253.583.28
Debt/Equity17.7%-22.6%22.1%62.9%35.0%1.0%44.7%
NetDebt/EBITDA-3.370.710.421.720.42-1.640.82
Profitability
MetricAVNS4DXCOHSNONCSMMEDTRInd. Median
Net Margin-9.7%-3,684.6%14.6%10.1%6.3%0.2%-5.7%
ROE-8.6%18.1%12.1%12.9%0.2%-8.6%
ROA-6.4%-264.3%12.4%6.1%8.0%0.2%-6.4%
EBITDA Margin-3.0%-818.8%24.0%25.6%30.6%9.4%5.2%
Growth + Dividend
MetricAVNS4DXCOHSNONCSMMEDTRInd. Median
Rev. Growth3.9%-26.0%2.0%39.1%6.5%7.4%
NI Growth-6.8%-62.9%16.7%
Div. Yield3.6%3.5%0.0%1.1%1.1%
Payout81.5%52.8%0.0%656.3%39.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on AVNS

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.